



November 14, 2022

To,

Manager (CDR)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, Dalal Street,
Mumbai-400001.

Ref: DR LALCHANDANI LABS LIMITED (Scrip Code: 541299)

Subject: Outcome of the Board Meeting dated 14.11.2022

Dear Sir/ Madam,

Please find enclosed herewith Unaudited Financial Results for the half year ended on September 30, 2022 along with Limited Review Report approved by the Board of Directors of the Company at its meeting held today i.e. November 14, 2022 in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

It is also intimated that the date of re-opening of trading window will be as per the following details:

Closure of Trading Window from	Closure of Trading Window till	Purpose of closure of trading window
01/10/2022	14/11/2022	Declaration of Un-Audited Financial Results for the half year ended September 30, 2022.

The said meeting of the Board of Directors commenced at 05.00 p.m. and concluded at 08.30 p.m.

Please take the same on your record.

Thanking You,

Yours Faithfully,

For DR LALCHANDANI LABS LIMITED



Arjan Lalchandani
Managing Director
DIN: 07014579

Encl: As Above



DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandanipathlab.com/>, Email id: info@lalchandanipathlab.com

Phone: 8010689689/ 8010998844

UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2022

Amount Rs. in Lacs

Sr.No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2022	31.03.2022	30.09.2021	31.03.2022	31.03.2021
		Un-audited	Audited	Un-audited	Audited	Audited
I	Revenue from Operations	228.39	325.77	802.10	1,127.87	978.00
II	Other Income	0.67	0.08	-	0.08	-
III	Total Revenue (I+II)	229.06	325.85	802.10	1,127.95	978.00
IV	Expenses					
	(a) Cost of materials consumed	74.67	56.22	267.66	323.88	360.59
	(b) Employee benefits expense	80.93	88.52	39.73	128.26	70.37
	(c) Finance Cost	48.30	33.21	23.62	56.83	35.38
	(d) Depreciation and amortisation expense	32.66	30.32	28.45	58.77	51.53
	(e) Other Expenses	89.77	135.45	300.05	435.50	322.39
	Total Expenses	326.32	343.73	659.51	1,003.24	840.26
V	Profit before exceptional and extraordinary items and tax (III - IV)	-97.26	-17.88	142.59	124.71	137.74
VI	Exceptional Items	-	-	-	-	-
VII	Profit extraordinary items and tax (V - VI)	-97.26	-17.88	142.59	124.71	137.74
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit before tax (VIII - IX)	-97.26	-17.88	142.59	124.71	137.74
X	Tax Expenses:					
	(1) Current Tax	0.00	-7.09	35.90	28.82	31.29
	(2) Deferred Tax	0.00	2.57	0.00	2.57	5.31
XI	Profit / (Loss) from Period from continuing operations (VII -VIII)	-97.26	-13.36	106.69	93.33	101.13
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	-97.26	-13.36	106.69	93.33	101.13
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)	-	-	-	-	-
	(a) Basic (Rs.)	-2.24	-0.31	2.46	2.15	2.33
	(b) Diluted (Rs.)	-2.24	-0.31	2.46	2.15	2.33

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14-11-2022.
2. There were no investor complaints received / pending as at 30th September 2022.
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment-wise reporting is not applicable.
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.

For Dr Lalchandani Labs Limited,



(Dr. Arjan Lalchandani)

Managing Director (DIN: 07014579)

New Delhi

14-Nov-2022

DR LALCHANDANI LABS LIMITED
(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi 110048.

Website: <http://lalchandaniopathlab.com/>

Email id: info@lalchandaniopathlab.com Phone: 8010689689/ 8010998844

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended	
		30.09.2022	31.03.2022
1	Shareholders' Funds		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	517.96	615.22
	(c) Money received against share warrants	-	-
	Sub-total-Shareholders' Funds	951.27	1,048.53
2	Share application money pending allotment		
3	Non-Current Liabilities		
	(a) Long Term Borrowings	554.87	261.84
	(b) Deferred Tax Liability	15.89	15.89
	(c) Other Long-Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-total-Non-Current Liabilities	570.76	277.73
4	Current Liabilities		
	(a) Short Term Borrowings	139.09	252.57
	(b) Trade Payables	-	-
	(i) Total Outstanding dues of micro enterprises and small enterprises	36.77	41.07
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	86.67	102.08
	(c) Other Current Liabilities	64.94	57.62
	(d) Short Term Provisions	28.82	32.64
	Sub-total-Current Liabilities	356.28	485.98
	TOTAL EQUITY AND LIABILITIES	1,878.31	1,812.24
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets	-	-
	(i) Tangible assets	529.18	531.36
	(ii) Intangible assets	40.17	43.76
	(b) Non-Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	120.05	121.64
	(d) Other Non-Current Assets	5.72	11.43
	Sub-total-Non-Current Assets	719.21	732.30

2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	154.86	155.60
	(c) Trade Receivables	454.69	422.53
	(d) Cash & cash equivalents	356.38	353.27
	(e) Short Term Loans & Advances	75.08	43.94
	(f) Other Current Assets	118.09	104.60
	Sub-total-Current Assets	1,159.10	1,079.94
	TOTAL ASSETS	1,878.31	1,812.24

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
(Managing Director DIN: 07014579)

New Delhi
14-Nov-2022

Cash Flow Statement for the Year Ended 30.09.2022

<u>Particulars</u>	<u>Amount</u>
A <u>Cash Flow from Operating Activities</u>	
Net Profit/(Loss) Before Tax	(97.26)
Adjustment For:	
Depreciation	32.66
Interest Expense	48.30
Asset Written Off	0.11
<u>Operating Profit Before Working Capital Changes</u>	<u>(16.19)</u>
 <u>Changes in Working Capital</u>	
Change in Sundry Debtors	(32.16)
Change in Other Current Assets & Non-Current Assets	(7.78)
Change in Trade Payables	(19.71)
Changes in Inventories	0.75
Change in Other Current Liabilities	7.32
Short Term Provisions	(3.82)
	<u>(55.40)</u>
	<u>(71.59)</u>
<u>Net Cash Flows from Operating Activities(A)</u>	<u>(71.59)</u>
 B <u>Cash Flow from Investing Activities</u>	
Purchase of Fixed Assets	(26.99)
Loans and Advances given	(29.55)
	<u>(56.54)</u>
<u>Net Cash Flow from Investing Activities (B)</u>	<u>(56.54)</u>
 C <u>Cash Flow from Financing Activities</u>	
Long Term Borrowings taken	293.03
Short Term Borrowings	(113.48)
Interest Paid	(48.30)
	<u>131.25</u>
<u>Net Cash Flow from Financing Activities (C)</u>	<u>131.25</u>
 <u>Net Change in Cash (A+B+C)</u>	<u>3.12</u>
Cash and Cash Equivalents at the Beginning of Year	<u>353.27</u>
Cash and Cash Equivalents at the End of Year	<u>356.38</u>

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
 (Managing Director DIN: 07014579)
 New Delhi
 14-Nov-2022



Jain Agarwal & Company

Chartered Accountants

LIMITED REVIEW REPORT

TO

**THE BOARD OF DIRECTORS OF
DR LALCHANDANI LABS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of Dr Lalchandani Labs Limited ("the Company") for the half year ended 30th September 2022 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Agarwal and Company

Chartered Accountants

Firm's Registration No.: 024866N



CA Karan Jain

(Partner)

Membership No.: 521992

Place: New Delhi

Date: 14th November 2022

UDIN No.: 22521992BDCMXU5394